SENP2 Regulates Hepatocellular Carcinoma Cell Growth by Modulating the Stability of β-catenin

  • Shen, Huo-Jian ;
  • Zhu, Hong-Yi ;
  • Yang, Chao ;
  • Ji, Fu
  • Published : 2012.08.31


SUMOylation has emerged as an important post-translational modification that modulates the localization, stability and activity of a broad spectrum of proteins. A dynamic process, it can be reversed by a family of SUMO-specific proteases (SENPs). However, the biological roles of SENPs in mammalian development and pathogenesis remain largely elusive. Here, we demonstrated that SENP2 plays a critical role in the control of hepatocellular carcinoma cell growth. SENP2 was found to be down-regulated in hepatocellular carcinoma (HCC) tissues and over-expression suppressed the growth and colony formation of HCC cells. In contrast, silencing of SENP2 by siRNAs promoted cancer cell growth. We further found that stability of ${\beta}$-catenin was markedly decreased when SENP2 was over-expressed. Interestingly, the decrease was dependent on the de-SUMOylation activity of SENP2, because over-expression of a SENP2 catalytic mutant form had no obviously effects on ${\beta}$-catenin. Our results suggest that SENP2 might play a role in hepatocellular carcinoma cell growth control by modulating the stability of ${\beta}$-catenin.


SENP2;${\beta}$-catenin;hepatocellular carcinoma;HepG2 cells


  1. Yeh JJ, Hsu NY, Hsu WH, et al (2005). Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung, 183, 177-83.
  2. Bawa-Khalfe T, Yeh ET (2010). SUMO Losing Balance: SUMO Proteases Disrupt SUMO Homeostasis to Facilitate Cancer Development and Progression. Genes Cancer, 1, 748-52.
  3. Cavard, C, S Colnot, V Audard, et al (2008). Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol, 4, 647-60.
  4. Cheng J, Bawa T, Lee P, et al (2006). Role of desumoylation in the development of prostate cancer. Neoplasia, 8, 667-76.
  5. Cheng J, Kang X, Zhang S, et al (2007). SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell, 131, 584-95.
  6. Chiu SY, Asai N, Costantini F, et al (2008). SUMO-specific protease 2 is essential for modulating p53-Mdm2 in development of trophoblast stem cell niches and lineages. PLoS Biol, 6, e310.
  7. David R (2010). Sumoylation: Targeting SUMO. Nat Rev Mol Cell Biol, 11, 387.
  8. Di Bacco A, Gill G (2006). SUMO-specific proteases and the cell cycle. An essential role for SENP5 in cell proliferation. Cell Cycle, 5, 2310-3.
  9. Geiss-Friedlander R, Melchior F (2007). Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol, 8, 947-56.
  10. Haindl M, Harasim T, Eick T, et al (2008). The nucleolar SUMOspecific protease SENP3 reverses SUMO modification of nucleophosmin and is required for rRNA processing. EMBO Rep, 9, 273-9.
  11. Hang J, Dasso M (2002). Association of the human SUMO-1 protease SENP2 with the nuclear pore. J Biol Chem, 277, 19961-6.
  12. Huang H, He X (2008). Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol, 20, 119-25.
  13. Itahana Y, Yeh ET, Zhang Y (2006). Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol, 26, 4675-89.
  14. Kang X, Qi Y, Zuo Y, et al (2010). SUMO-specific protease 2 is essential for suppression of polycomb group proteinmediated gene silencing during embryonic development. Mol Cell, 38, 191-201.
  15. Lam AP, Gottardi CJ (2011). Beta-catenin signaling: a novel mediator of fibrosis and potential therapeutic target. Curr Opin Rheumatol, 23, 562-7.
  16. Li SJ, Hochstrasser M (1999). A new protease required for cellcycle progression in yeast. Nature, 398, 246-51.
  17. MacDonald BT, Tamai K, He X (2009). Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell, 17, 9-26.
  18. Vertegaal AC (2010). SUMO chains: polymeric signals. Biochem Soc Trans, 38, 46-49.
  19. Wang Y, Dasso M (2009). SUMOylation and deSUMOylation at a glance. J Cell Sci, 122, 4249-52.
  20. White BD, Chien AJ, Dawson DW (2012). Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterology, 142, 219-32.
  21. Woo CH, Abe J (2010). SUMO--a post-translational modification with therapeutic potential? Curr Opin Pharmacol, 10, 146-55.
  22. Zhang XF, Tan X, Zeng G, et al (2010). Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling. Hepatology, 52, 954-65.

Cited by

  1. Aberrant sumoylation signaling evoked by reactive oxygen species impairs protective function of Prdx6 by destabilization and repression of its transcription vol.281, pp.15, 2014,
  2. SENP2 regulated the stability of β-catenin through WWOX in hepatocellular carcinoma cell vol.35, pp.10, 2014,
  3. Identification of 1,2,5-Oxadiazoles as a New Class of SENP2 Inhibitors Using Structure Based Virtual Screening vol.54, pp.3, 2014,
  4. Inhibition of SENP5 suppresses cell growth and promotes apoptosis in osteosarcoma cells vol.7, pp.6, 2014,
  5. Functional Proteomics Study Reveals SUMOylation of TFII-I is Involved in Liver Cancer Cell Proliferation vol.14, pp.6, 2015,
  6. SUMO-specific protease 6 promotes gastric cancer cell growth via deSUMOylation of FoxM1 vol.36, pp.12, 2015,
  7. Immortalization of epithelial cells in oral carcinogenesis as revealed by genome-wide array comparative genomic hybridization: A meta-analysis vol.38, pp.S1, 2015,
  8. Protein SUMOylation modification and its associations with disease vol.7, pp.10, 2017,
  9. SUMO pathway components as possible cancer biomarkers vol.11, pp.11, 2015,